You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • P275 Comparing clinically relevant improvement with umeclidinium/vilanterol and tiotropium/olodaterol in symptomatic copd: a randomised non-inferiority crossover trial

Article Text

Article menu

Download PDFPDF

Declarations of Interest
P275 Comparing clinically relevant improvement with umeclidinium/vilanterol and tiotropium/olodaterol in symptomatic copd: a randomised non-inferiority crossover trial
Free

Abstract

This study (204990 [NCT02799784]) was funded by GSK.

C Compton, AR Sousa, D Lipson, I Naya and S Patel are employees of GSK and hold stocks/shares in GSK.

L Tombs is a contingent worker on assignment at GSK.

G Feldman has no disclosures to declare.

B Alcázar Navarrete declares the following conflicts of interest: personal fees and non-financial support from Boehringer Ingelheim, Chiesi and GSK; grants, personal fees and non-financial support from Novartis AG and Laboratorios Menarini; and personal fees from Astra-Zeneca and Gebro. In addition, Dr. Alcázar Navarrete has a patent (P201730724) pending.

https://doi.org/10.1136/thoraxjnl-2017-210983.473

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.